Persistence and Adherence to ICS/LABA Drugs in UK Patients with Asthma: A Retrospective New-User Cohort Study

Autor: Quratul Ann, Henrik Svedsater, Christen Gray, Mark Nixon, Mugdha Gokhale, David Hinds, Mounika Parimi, Naomi J. Boxall
Rok vydání: 2020
Předmět:
Male
Budesonide
030213 general clinical medicine
Cohort Studies
chemistry.chemical_compound
0302 clinical medicine
ICS/LABA
Budesonide
Formoterol Fumarate Drug Combination
New user
Pharmacology (medical)
Anti-Asthmatic Agents
Child
Original Research
Aged
80 and over
Beclomethasone
General Medicine
Middle Aged
respiratory system
030220 oncology & carcinogenesis
Corticosteroid
Female
Vilanterol
medicine.drug
Adult
medicine.medical_specialty
Adolescent
medicine.drug_class
Discontinuation
Chlorobenzenes
Fluticasone propionate
Medication Adherence
Persistence
Young Adult
03 medical and health sciences
Internal medicine
Administration
Inhalation
medicine
Humans
Benzyl Alcohols
Aged
Retrospective Studies
Asthma
business.industry
Beclometasone dipropionate
medicine.disease
United Kingdom
Androstadienes
chemistry
Adherence
Formoterol
business
Zdroj: Advances in Therapy
ISSN: 1865-8652
0741-238X
Popis: Introduction Asthma is associated with significant economic burden. Inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) combination therapies are considered mainstays of treatment. We describe real-world use of ICS/LABAs by comparing treatment persistence and adherence among patients with asthma in the United Kingdom initiating fluticasone furoate/vilanterol (FF/VI) versus budesonide/formoterol (BUD/FM) or beclometasone dipropionate/formoterol (BDP/FM). Methods A retrospective new-user active comparator database study was conducted in the IQVIA Medical Research Database. Propensity score (PS) matching was performed for FF/VI versus BUD/FM, and FF/VI versus BDP/FM. The primary objective was to compare patient treatment persistence (time to discontinuation), while secondary objectives included assessing adherence (mean proportion of days covered [PDC] with medication in the study period) and the proportions of patients achieving ≥ 50% and ≥ 80% PDC. Results New users of FF/VI (N = 966), BUD/FM (N = 5931) and BDP/FM (N = 9607) were identified and PS-matched: FF/VI (n = 945) versus BUD/FM (n = 3272), and FF/VI (n = 902) versus BDP/FM (n = 3465). At 12 months, treatment persistence was 69% (FF/VI), 53% (BUD/FM) and 57% (BDP/FM). The likelihood of treatment discontinuation within 12 months after initiation with FF/VI was 35% lower than with BUD/FM and 31% lower than for BDP/FM (both p
Databáze: OpenAIRE
Externí odkaz: